| Margins | EBITDA margins improved YoY from 38.1% to 39.6%. |
|---|---|
| Demand visibility | Strong, with scheduled deliveries concentrated in H2 FY27. |
| Management confidence | High; citing strong underlying demand and historical alignment. |
Growth
Revenue fell 22.6% YoY to ₹4,182 Mn; PAT decreased 11.7% YoY to ₹1,199 Mn.
Outlook
Positioned to capture momentum in H2; maintenance of industry-leading margin profile via cost efficiencies.
Risks
Timing shifts in deliveries to key customers impacted Q1 performance; dependency on second-half concentration.
Last quarter's promises, checked
Delivered
- Guided 20% historical growth → delivered 18% FY26 revenue growth (= BEAT)
- Guided 30% EBITDA growth → delivered 31% FY26 EBITDA growth (= BEAT)
- Guided 30% PAT growth → delivered 31% FY26 PAT growth (= BEAT)
Partly delivered
- Guided 38-40% EBITDA margins → delivered 39.6% in Q1FY27 (= PARTIAL)
Missed
- Guided Q1FY27 momentum → delivered -22.6% YoY revenue growth (= MISS)
Investor Presentation filed with NSE, NSE: ANTHEM. Summary written with AI assistance from the document.
Anthem Biosciences Ltd: key numbers
- Share price
- ₹873.60
- Market cap
- ₹49,201 Cr
- Revenue (annual)
- ₹2,124 Cr
- Net profit (annual)
- ₹591.8 Cr
- P/E (TTM)
- 85.4×Sector 50.4×
- Promoter holding
- 71.42%-3.26% QoQ
- FII holding
- 2.57%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anthem Biosciences Ltd
All →Anthem Biosciences Other Announcement
Designated Person Viridity Tone LLP sold shares of Anthem Biosciences Ltd worth ₹82.67 Crore via market sale.
- Value
- ₹82.67 Cr
Anthem Biosciences Legal & Regulatory
Anthem Biosciences Ltd announced the settlement of an upside sharing amount of ₹127.68 Crore related to a prior divestment, following shareholder approval.
- Value
- ₹127.7 Cr
Anthem Biosciences Earnings Call Transcript: Key Takeaways
Revenue fell 25% YoY due to deferred deliveries, though management claims a record order book will drive second-half recovery. While EBITDA margins remain high at 39.6%, the quarter reflects high lumpiness in the CRDMO business.
Anthem Biosciences Q1 FY27 Results: Net Profit ₹119.9 Cr, Down 11.7% YoY
Anthem Biosciences Ltd reported revenue from operations of ₹418.2 Cr (-22.6% YoY) and net profit of ₹119.9 Cr (-11.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹119.9 Cr · -11.7% YoY
Anthem Biosciences Earnings Call: Key Takeaways
Anthem Biosciences delivered record Q4 performance with FY26 revenue of ₹2,280cr and 43.4% EBITDA margins, driven by CRDMO strength.
Anthem Biosciences Earnings Call: Key Takeaways
Anthem delivered robust FY26 growth, overcoming destocking challenges in their core CRDMO segment.